Xerient is focused on unmet needs in cancer treatment, particularly in abdominal and gastrointestinal cancers. Xerient is pursuing the development of novel therapeutics and diagnostic technologies that can dramatically improve the survival of these patients. The company is introducing a portfolio of products that will address hard to treat cancers in the abdominal/GI area, beginning with solutions for pancreatic cancer.